ARKG Holdings of Exact Sciences Corp. (EXAS) - Updated Daily
Liquid BiopsyGenomicsGenetic Testing
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 9.66% | $12.00b |
| 🏋🏿♂️Weight Rank In ARKG | 🌏Country |
| 1 | 🇺🇸United States |
| 🏋️♀️Weight Rank Across All Funds | 💳ARK Estimated Cost Average |
| 7 | $94.56 |
| 🎫ARK Ownership Percent | |
| 1.39% | |
| Description | |
|---|---|
| exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences' noninvasive colon cancer screening test, visit cologuardtest.com | |
| Website | |
| https://www.exactsciences.com/ |
Other ETFs That Hold EXAS
Research Notes and Commentary for EXAS
No Research Notes Found for EXAS